Expert Biological Data Analysis & Bioinformatics Services
Tailored Data Science Solutions to Accelerate Biopharma, Cosmetic, and Clinical R&D.
Transforming Complex Biological Datasets into Actionable Insights
AltraBio specializes in advanced biological data analysis, empowering life science leaders to unlock meaningful insights from flow cytometry, mass cytometry (IMC), single-cell, and multi-omics data. Combining cutting-edge AI, machine learning, and rigorous biostatistics, we serve as a trusted R&D partner for top pharmaceutical companies, biotech startups, dermo-cosmetic leaders, and university hospitals worldwide.
Explore Our Core Analytical Capabilities:
Cytometry Analysis: Automated gating, high-dimensional panel analysis, and biomarker discovery.
Omics & Multi-Omics: Single-cell RNA-seq, bulk transcriptomics, proteomics, and target identification.
Clinical & Medical Data: Patient stratification, real-world data mining, and statistical modeling.
Our Collaboration Models: From Collaborative R&D to CRO Services
R&D Consortia & Collaborative Partnerships
Development of proprietary computational tools and bioinformatics pipelines within regional, European, and international research consortia.
Bioinformatics Subcontracting & CRO Services
Tailored data analysis services for biopharma companies and university hospitals. Over hundreds of successful projects delivered for top-10 pharmaceutical groups and global cosmetic leaders.
Why Leading Biopharma Companies Choose AltraBio
« Supervised approach is really a mature approach, I think there is an absolute need for having this solution… »
« The quality of the results we got from AB was quite remarkable in the good »
« AltraBio is viewed as automating subject matter experts, with the ability to do the same work. It allows us to free up subject matter experts at scale so a subject matter expert doesn’t have to spend as much time doing gating or reviewing gatings, and it all hinges on the quality that they provide. So for us, that’s the biggest selling point; the quality allow us to be able to say, OK this technology is almost as good as subject matter experts in this domain, and the pricing and the speed make it such that it becomes a feasible solution for us to say we can free up the scientists to do other things and this part can be handled by AltraBio. »
« They do cutting-edge work, we clearly like the innovation part »
« In clinical trials, we could get thousands of samples for different panels… The scale is clearly so big, not many companies can do this kind of work in production mode, on the labor scale »
« They fit clients’ need. »
« Even in the age of generative AI, Altrabio’s two decades of expertise in maths, stats, biology, and medical science remain invaluable. They don’t just talk, they do. No flashy marketing, no inflated costs, just solid, thoughtful work from study design to actionable insights. A trusted partner, for twenty years, in a world full of noise. Highly recommend working with them to make real sense of your complex biomedical and omics data. »
« Exceptional »
« We really appreciate AltraBio because they provide one-stop full service, so we don’t need to worry about a lot of former problems, and also quality of results »
« Top of the field »
« They are highly efficient and agile; you won’t interact with much people, so they are quick to respond and provide high-quality service »
« If there is some problem, or troubleshooting is necessary, or some change in the workflow, they are very flexible.»
« Automated gating is there… In 2018, when automated gating was discussed at CYTO, some people stood up and said: “No! This is not going to work. Gating has been done by scientists & experts, and you can’t just put a computer to do their job.” We know now that it is not true because the Altrabio’s solutions are now doing it. It is pretty amazing. »
« This is accurate; we can use it at scale, so we don’t have to do the manual gating. »
« They do that extra bit of QC on their hand; they also check the transfers and put that extra effort in to make sure that what we do is accurate »
« The work we do with AltraBio is a partnership. I’ll make an example of the last analysis that we did; there were some timelines that needed to be met and they stepped in and said “OK we‘ll get this done in a few days”, not in a week, not in a month … When you have that relationship, when you understand the value and you understand the timelines of the customer, that felt really like a partnership and I think we’re heading in that direction… »
Ready to Accelerate Your Biological R&D Projects?
News
March 2026
Dermocosmetics Omics Analysis: AltraBio at Cosmetotest
The international symposium Cosmetotest is a premier event dedicated [...]
saRNA Vaccine Transcriptomics: Insights from the COVAC1 Trial
The COVID-19 pandemic highlighted RNA vaccination as a rapid [...]
February 2026
SNV Analysis Pipeline for Clownfish Genetics | AltraBio Case Study
Animal pigmentation patterns are essential for survival and behavior. [...]
Machine Learning Identifies Key IPF Prognostic Biomarkers in ISABELA Trials
Introduction A major study recently published in ERJ Open [...]
Latest Publications
2012
Idbaih, Ahmed; Ducray, François; Dehais, Caroline; Courdy, Célia; Carpentier, Catherine; de Bernard, Simon; Uro-Coste, Emmanuelle; Mokhtari, Karima; Jouvet, Anne; Honnorat, Jérôme; Chinot, Olivier; Ramirez, Carole; Beauchesne, Patrick; Benouaich-Amiel, Alexandra; Godard, Joël; Eimer, Sandrine; Parker, Fabrice; Lechapt-Zalcman, Emmanuelle; Colin, Philippe; Loussouarn, Delphine; Faillot, Thierry; Dam-Hieu, Phong; Elouadhani-Hamdi, Selma; Bauchet, Luc; Langlois, Olivier; Guerinel, Caroline Le; Fontaine, Denys; Vauleon, Elodie; Menei, Philippe; Fotso, Marie Janette Motsuo; Desenclos, Christine; Verrelle, Pierre; Ghiringhelli, François; Noel, Georges; Labrousse, François; Carpentier, Antoine; Dhermain, Frédéric; Delattre, Jean-Yves; Figarella-Branger, Dominique
SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas Journal Article
In: PLoS One, vol. 7, no. 10, pp. e45950, 2012, ISSN: 1932-6203.
@article{pmid23071531,
title = {SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas},
author = {Ahmed Idbaih and François Ducray and Caroline Dehais and Célia Courdy and Catherine Carpentier and Simon de Bernard and Emmanuelle Uro-Coste and Karima Mokhtari and Anne Jouvet and Jérôme Honnorat and Olivier Chinot and Carole Ramirez and Patrick Beauchesne and Alexandra Benouaich-Amiel and Joël Godard and Sandrine Eimer and Fabrice Parker and Emmanuelle Lechapt-Zalcman and Philippe Colin and Delphine Loussouarn and Thierry Faillot and Phong Dam-Hieu and Selma Elouadhani-Hamdi and Luc Bauchet and Olivier Langlois and Caroline Le Guerinel and Denys Fontaine and Elodie Vauleon and Philippe Menei and Marie Janette Motsuo Fotso and Christine Desenclos and Pierre Verrelle and François Ghiringhelli and Georges Noel and François Labrousse and Antoine Carpentier and Frédéric Dhermain and Jean-Yves Delattre and Dominique Figarella-Branger},
doi = {10.1371/journal.pone.0045950},
issn = {1932-6203},
year = {2012},
date = {2012-01-01},
urldate = {2012-01-01},
journal = {PLoS One},
volume = {7},
number = {10},
pages = {e45950},
abstract = {Anaplastic oligodendrogliomas (AOD) are rare glial tumors in adults with relative homogeneous clinical, radiological and histological features at the time of diagnosis but dramatically various clinical courses. Studies have identified several molecular abnormalities with clinical or biological relevance to AOD (e.g. t(1;19)(q10;p10), IDH1, IDH2, CIC and FUBP1 mutations).To better characterize the clinical and biological behavior of this tumor type, the creation of a national multicentric network, named "Prise en charge des OLigodendrogliomes Anaplasiques (POLA)," has been supported by the Institut National du Cancer (InCA). Newly diagnosed and centrally validated AOD patients and their related biological material (tumor and blood samples) were prospectively included in the POLA clinical database and tissue bank, respectively.At the molecular level, we have conducted a high-resolution single nucleotide polymorphism array analysis, which included 83 patients. Despite a careful central pathological review, AOD have been found to exhibit heterogeneous genomic features. A total of 82% of the tumors exhibited a 1p/19q-co-deletion, while 18% harbor a distinct chromosome pattern. Novel focal abnormalities, including homozygously deleted, amplified and disrupted regions, have been identified. Recurring copy neutral losses of heterozygosity (CNLOH) inducing the modulation of gene expression have also been discovered. CNLOH in the CDKN2A locus was associated with protein silencing in 1/3 of the cases. In addition, FUBP1 homozygous deletion was detected in one case suggesting a putative tumor suppressor role of FUBP1 in AOD.Our study showed that the genomic and pathological analyses of AOD are synergistic in detecting relevant clinical and biological subgroups of AOD.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Funding
